<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-147918</identifier>
<setSpec>0300-2896</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment</dc:title>
<dc:description xml:lang="en">Tuberculosis risk is increased in patients with chronic inflammatory diseases receiving any immunosuppressive treatment, notably tumor necrosis factor (TNF) antagonists therapy. Screening for the presence of latent infection with Mycobacterium tuberculosis and targeted preventive treatment to reduce the risk of progression to TB is mandatory in these patients. This Consensus Document summarizes the current knowledge and expert opinion of biologic therapies including TNF-blocking treatments. It provides recommendations for the use of interferon-gamma release assays (IGRA) and tuberculin skin test (TST) for the diagnosis of latent tuberculosis infection in these patients, and for the type and duration of preventive therapy (AU)</dc:description>
<dc:creator>Martínez Lacasa, Xavier</dc:creator>
<dc:creator>Sánchez Martínez, Paquita</dc:creator>
<dc:creator>García Gasalla, Mercedes</dc:creator>
<dc:creator>Mir Viladrich, Isabel</dc:creator>
<dc:creator>Solano-López, Guillermo</dc:creator>
<dc:creator>López Longo, Francisco Javier</dc:creator>
<dc:creator>García García, José Maria</dc:creator>
<dc:creator>Daudén Tello, Esteban</dc:creator>
<dc:creator>Taxonera Samso, Carlos</dc:creator>
<dc:creator>Dorca Sargatal, Jordi</dc:creator>
<dc:creator>Arias-Guillén, Miguel</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El riesgo de enfermar de tuberculosis ha aumentado en los pacientes con enfermedades inflamatorias crónicas que reciben tratamiento inmunosupresor, en particular en aquellos tratados con terapia anti-TNF (del inglés tumor necrosis factor). En estos pacientes es obligatoria la detección de la infección tuberculosa latente y el tratamiento de dicha infección, dirigido a reducir el riesgo de progresión a enfermedad tuberculosa. Este documento de consenso resume la opinión de expertos y los conocimientos actuales sobre tratamientos biológicos, incluidos los bloqueantes del TNF. Se establecen recomendaciones para la utilización de las técnicas de liberación de interferón-gamma (IGRA) y la prueba de la tuberculina (PT) para el diagnóstico y el tratamiento de la infección tuberculosa latente (AU)</dc:description>
<dc:source>Arch Bronconeumol;52(1): 36-45, ene. 2016. tab, ilus</dc:source>
<dc:identifier>ibc-147918</dc:identifier>
<dc:title xml:lang="es">Documento de consenso sobre la prevención y el tratamiento de la tuberculosis en pacientes candidatos a tratamiento biológico</dc:title>
<dc:subject>^d1716^s22074</dc:subject>
<dc:subject>^d14778^s22067</dc:subject>
<dc:subject>^d53483^s22067</dc:subject>
<dc:subject>^d28563^s22054</dc:subject>
<dc:subject>^d14778^s22054</dc:subject>
<dc:subject>^d1716^s22048</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d14778^s22080</dc:subject>
<dc:subject>^d1716^s22066</dc:subject>
<dc:subject>^d54661^s22074</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d22870</dc:subject>
<dc:subject>^d1716^s22045</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d54661^s22045</dc:subject>
<dc:subject>^d54661^s22048</dc:subject>
<dc:subject>^d53483^s22054</dc:subject>
<dc:type>article</dc:type>
<dc:date>201601</dc:date>
</metadata>
</record>
</ibecs-document>
